Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the outcome of patients with lower urinary symptoms suggestive of benign prostatic hyperplasia and treated with alfuzosin 10 mg once daily for 3 months in China

Trial Profile

Study of the outcome of patients with lower urinary symptoms suggestive of benign prostatic hyperplasia and treated with alfuzosin 10 mg once daily for 3 months in China

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Alfuzosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ALF-ONE
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Oct 2006 Status change
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top